Upgrade to SI Premium - Free Trial

Moderna (MRNA) Mix & Match Approval Means Booster Can Follow Any Other Vaccine - Piper Sandler

October 21, 2021 9:20 AM
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $445.00 price target on Moderna (NASDAQ: MRNA) after the FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles